Post-hoc analysis of real-world retrospective study on neoadjuvant chemotherapy combined with immunotherapy for stage I-III non-small cell lung cancer
Neoadjuvant chemotherapy combined with immunotherapy significantly improves pCR rates, ORR, and EFS compared to chemotherapy alone, with manageable adverse events. The predictive model provides valuable insights for clinical decision-making.
Authors
- ShengHan Wang
- Yanbin Zhao (ORCID: https://orcid.org/0000-0002-1350-8570)
- Yanchi Shao
- Wuyuntanghesi
- Weiwei Yang
- Yingchun Yu
- Lei Song
Institutions
- Harbin Medical University (CN)
- Jilin University (CN)
- Third Affiliated Hospital of Harbin Medical University (CN)
- Zhejiang Lab (CN)
- First Hospital of Jilin University (CN)
- Universities of Giessen and Marburg Lung Center (DE)
- Cardio-Pulmonary Institute (DE)
- Nagasaki University (JP)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2026-01-02
- DOI
- https://doi.org/10.3389/fimmu.2025.1576951
- Primary Topic
- Lung Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Harbin Medical University
- National Natural Science Foundation of China